DK0555331T3 - N-substituerede imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser - Google Patents

N-substituerede imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser

Info

Publication number
DK0555331T3
DK0555331T3 DK91919894.5T DK91919894T DK0555331T3 DK 0555331 T3 DK0555331 T3 DK 0555331T3 DK 91919894 T DK91919894 T DK 91919894T DK 0555331 T3 DK0555331 T3 DK 0555331T3
Authority
DK
Denmark
Prior art keywords
butyl
compounds
image
treatment
phenethyl
Prior art date
Application number
DK91919894.5T
Other languages
English (en)
Inventor
David B Reitz
Robert E Manning
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0555331T3 publication Critical patent/DK0555331T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK91919894.5T 1990-10-31 1991-10-28 N-substituerede imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser DK0555331T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/606,806 US5087634A (en) 1990-10-31 1990-10-31 N-substituted imidazol-2-one compounds for treatment of circulatory disorders

Publications (1)

Publication Number Publication Date
DK0555331T3 true DK0555331T3 (da) 1996-05-13

Family

ID=24429549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91919894.5T DK0555331T3 (da) 1990-10-31 1991-10-28 N-substituerede imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser

Country Status (12)

Country Link
US (1) US5087634A (da)
EP (1) EP0555331B1 (da)
AT (1) ATE137226T1 (da)
AU (1) AU8867291A (da)
CA (1) CA2094390C (da)
DE (1) DE69119089T2 (da)
DK (1) DK0555331T3 (da)
ES (1) ES2086003T3 (da)
GR (1) GR3019768T3 (da)
IE (1) IE913814A1 (da)
PT (1) PT99392B (da)
WO (1) WO1992007834A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5187271A (en) * 1991-02-28 1993-02-16 G. D. Searle & Co. N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
US6008368A (en) * 1993-04-28 1999-12-28 G. D. Searle & Co. Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5861420A (en) * 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
PT626969E (pt) * 1992-02-11 2000-11-30 Smithkline Beecham Corp Inibidores de co.a-it e de p.a.f.
US5663053A (en) * 1992-02-11 1997-09-02 Smithkline Beecham Corporation Inhibition of inflammatory lipid mediators
KR100261403B1 (ko) * 1992-02-13 2000-07-01 로즈 암스트롱 키랄 에틸 (5-아미노-1,2-디히드로-2-메틸-3-페닐피리도(3,4-b)피라진-7-일)카르바메이트의 제조 방법
TW215434B (da) * 1992-03-07 1993-11-01 Hoechst Ag
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
WO1994008990A1 (en) * 1992-10-13 1994-04-28 G.D. Searle & Co. N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
WO1994008989A1 (en) * 1992-10-13 1994-04-28 G.D. Searle & Co. N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treatment of circulatory disorders
EP0690854B1 (en) * 1993-03-24 2000-07-12 G.D. Searle & Co. 1-phenyl-imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
DE4317321A1 (de) * 1993-05-25 1994-12-01 Bayer Ag Substituierte 2,4-Imidazolidindione
US5451597A (en) * 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
EP0685467A4 (en) * 1993-12-16 1996-04-17 Nippon Kokan Kk PYRIMID DERIVATIVES AND MEDICAL PREPARATION.
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
ATE429927T1 (de) 2000-02-04 2009-05-15 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
EP3425059A1 (en) 2002-05-09 2019-01-09 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1809759B1 (en) 2004-10-06 2013-09-11 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US20070014733A1 (en) * 2005-01-31 2007-01-18 O'donnell John P Hydroxylated nebivolol metabolites
CA2610694A1 (en) 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
ES2434215T3 (es) 2007-04-18 2013-12-16 Tethys Bioscience, Inc. Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2011210508B2 (en) 2010-02-01 2015-01-29 The Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
EP2555692A2 (en) 2010-04-08 2013-02-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012284039B2 (en) 2011-07-18 2017-03-30 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
TWI643845B (zh) 2012-05-11 2018-12-11 重植治療公司 隱花色素調節劑之含咔唑磺醯胺類
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (da) *
BE621842A (da) * 1962-08-27
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione
US4294972A (en) * 1978-06-15 1981-10-13 Beecham Group Limited 1,2-Disubstituted oxo triazolidine
NZ215487A (en) * 1985-03-16 1990-01-29 Wellcome Found Aryl derivatives, pharmaceutical compositions thereof and preservation of cut flowers
US4677131A (en) * 1985-11-01 1987-06-30 Merck & Co., Inc. Cyclic ureas as dermal penetration enhancers
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
FR2659967B1 (fr) * 1990-03-20 1992-07-24 Sanofi Sa Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
IE913814A1 (en) 1992-05-22
PT99392A (pt) 1992-09-30
AU8867291A (en) 1992-05-26
PT99392B (pt) 1999-04-30
US5087634A (en) 1992-02-11
GR3019768T3 (en) 1996-07-31
CA2094390C (en) 2002-01-29
EP0555331A1 (en) 1993-08-18
WO1992007834A1 (en) 1992-05-14
ES2086003T3 (es) 1996-06-16
CA2094390A1 (en) 1992-05-01
ATE137226T1 (de) 1996-05-15
EP0555331B1 (en) 1996-04-24
DE69119089T2 (de) 1996-10-17
DE69119089D1 (de) 1996-05-30

Similar Documents

Publication Publication Date Title
DK0555331T3 (da) N-substituerede imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser
DK0579766T3 (da) N-Arylheteroarylalkyl-imidazol-2-on-forbindelser til behandling af kredsløbsforstyrrelser
DK0527851T3 (da) 1H-Substituerede 1,2,4-triazolforbindelser til behandling af kardiovaskulære forstyrrelser
DK0619819T3 (da) 1-Arylheteroarylalkyl-substituerede 1H-1,2,4-triazolforbindelser til behandling af kredsløbsforstyrrelser
NO963450D0 (no) Heterocykliske aromatiske oksazolforbindelser og deres anvendelse
DK5389A (da) Substituerede pyrroler, pyrazoler og triazoler, fremgangsmaader til deres fremstilling samt deres anvendelse som angiotensin ii-antagonister
AR050598A2 (es) Composicion funguicida sinergica, procedimiento para combatir hongos nocivos y uso de los compuestos que integran dicha composicion para la preparacion de dichas mezclas sinergicas
PE20030541A1 (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13
NO955192D0 (no) Imidazol[1,2-aÅpyrazin-4-on, fremstilling derav og medikament inneholdende forbindelsen
KR960701041A (ko) 순환장애의 치료를 위한 1-페닐-이미다졸-2-온 비페닐 메틸 화합물(1-phenyl-imidazol-2-one biphenylmethyl compounds for treatmetnt of circulatory disorders)
FI940324A (fi) 1-(N-(halo-3-pyridyylimetyyli))-N-metyyliamino-1-alkyyliamino-2-nitroetyleenijohdannaiset kirppujen torjumiseksi kotieläimissä
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
DK0664802T3 (da) N-Arylheteroarylalkyl-1-phenyl-imidazol-2-on-forbindelser til behandling af kredsløbssygdomme
TR199501278A2 (tr) Alkil-5-metilsülfonil-benzoilguanidin türevleri.
ES8104252A1 (es) Procedimiento de preparacion de nuevos derivados halogenadosde isopropilamino-pirimidina
NO994303L (no) Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre
NO157214C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolcarboxylsyrederivater.
DE59304359D1 (de) Ketorolac-Derivat mit wesentlich geringerer gastrointestinaler Reizung und Ulzeration